Gold Falls 1%; Charter Communications Shares Fall After Q3 Results
U.S. stocks gained Friday, led by Nasdaq +1.5%, as jobs beat forecasts. Gogo and JFrog surged, while DraftKings and Biodesix plunged.
Stocks · News reference
Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management
The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects patient adherence to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biodesix Reports Third Quarter 2026 Financial Results and Updates Full-Year Outlook
Biodesix, Inc. announced its third-quarter 2026 financial results, reporting $24 million in revenue and revising its full-year 2026 revenue guidance to $101 million to $103 million.
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. announced that members of its leadership team will participate in the UBS Global Healthcare Conference and the Craig-Hallum Alpha Select Conference in November 2026.
Biodesix to Report Third Quarter 2026 Financial Results
Biodesix, Inc. announced it will release its financial results for the third quarter ended September 30, 2026, on November 5, 2026.
Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis."
Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a Lung Nodule
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases.